Pfizer reaffirmed $10–$15 billion for business development, with focus on immunology and cardiometabolic expansion. CEO Bourla says national security concerns are central to U.S. drug ...

Pfizer recently said it wouldn't continue development of its weight loss candidate danuglipron, a once-daily pill, after a patient in a clinical trial experienced liver injury -- the problem ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

In 2009, she was hired by Pfizer as diversity and inclusion lead of worldwide pharmaceutical operations, but she swiftly moved to work as the executive director of diversity and inclusion of Morgan ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump's planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...

Pfizer’s effective tax rate on Reported (2) income for the first quarter of 2025 is negative, primarily due to favorable global income tax resolutions in multiple tax jurisdictions spanning ...

Pfizer Price Performance Shares of Pfizer stock opened at $22.95 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer has a 52 week ...

- Pfizer Inc. (NYSE: PFE) today held its Annual Meeting of Shareholders. Preliminary results from the Annual Meeting indicate that the company's 13 director nominees were re-elected to one-year terms ...

Pfizer's PFE non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products from Seagen. The trend ...

Precision oncology company Guardant Health (Nasdaq: GH) has announced a strategic collaboration with Pfizer (NYSE: PFE) to support the development and commercialization of the US pharma giant’s cancer ...